CAMP4 Q3 net loss $15.1M, cash $75.3M; advances CMP-002 with up to $100M placement

Camp4 Therapeutics Corp

2025-Q3 EPS reported -$1.78 revenue$3,150,000

Cash, equivalents, and marketable securities $75.3M at Sept 30, up from $39.1M at June 30.
Private placement initially closed $50M with potential proceeds up to $100M to fund CMP-002.
Initiated GLP toxicology studies for CMP-002; Phase 1/2 trial expected as early as H2 2026.
Strategic decision to pursue partnership for further development of CMP-001 (urea cycle disorders).
Net loss $15.1M for Q3 2025 vs $13.5M for Q3 2024; R&D expenses $9.4M, G&A $4.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.